Morgan Stanley (NYSE:MS) analyst Tejas Savant maintained a Buy rating on 10x Genomics (NASDAQ:TXG) Inc on Wednesday, setting a price target of $145, which is approximately 12.40% above the present share price of $129.
Savant expects 10x Genomics Inc to post earnings per share (EPS) of -$0.41 for the fourth quarter of 2020.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in 10x Genomics, with an average price target of $137.6.
The analysts price targets range from a high of $165 to a low of $100.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $42.91 million and a net profit of -$39.42 million. The company's market cap is $13.78 billion.
According to TipRanks.com, Morgan Stanley analyst Tejas Savant is currently ranked with 2 stars on a 0-5 stars ranking scale, with an average return of 4.2% and a 66.67% success rate.
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company's products include Single Cell Gene Expression, Immune Profiling, CNV, ATAC, and Genome and Exome. 10X Genomics was founded by Serge Saxonov, Ben Hindson, Kevin D. Ness and Eduard Diviu Terradas on July 2, 2012 and is headquartered in Pleasanton, CA.